Evidence map›Paper›PMID 41895703›Full record

Trial reportChest2026

A Randomized, Placebo-Controlled, Double-Blind, Crossover Trial of Inhaled Nitric Oxide in Patients With Mild-to-Severe COPD.

Sophie É Collins, Miranda Kirby, Benjamin M Smith, Zahrah H Rampuri, Desi P Fuhr, Samira Rowland, Andrew R Brotto, Rhonda J Rosychuk, Stephanie Thompson, Jason Weatherald and 2 more

Registry-linked trialAbstract readClinical Trial, Phase IClinical Trial, Phase IIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Chest, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03679312 (The Effect of Inhaled Nitric Oxide on Dyspnea and Exercise Tolerance in COPD), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03679312 phase1 / phase2completednot on this map

The Effect of Inhaled Nitric Oxide on Dyspnea and Exercise Tolerance in COPD

TypeinterventionalSponsorUniversity of AlbertaRan2018 to 2023Enrolled140ConditionsDyspneaArmsNitric Oxide, Placebo
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Sophie É CollinsDivision of Pulmonary Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada; Faculty of Rehabilitation Medicine, University of Alberta, Edmonton, AB, Canada.
Miranda KirbyDepartment of Physics, Toronto Metropolitan University, Toronto, ON, Canada.
Benjamin M SmithDepartment of Medicine, McGill University, Montreal, QC, Canada; Department of Medicine, Columbia University, New York, NY.
Zahrah H RampuriDivision of Pulmonary Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada.
Desi P FuhrDivision of Pulmonary Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada.
Samira RowlandDivision of Pulmonary Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada; Faculty of Rehabilitation Medicine, University of Alberta, Edmonton, AB, Canada.
Andrew R BrottoDivision of Pulmonary Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada; Faculty of Kinesiology, Sport, and Recreation, University of Alberta, Edmonton, AB, Canada.
Rhonda J RosychukDepartment of Pediatrics, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada.
Stephanie ThompsonDivision of Nephrology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada.
Jason WeatheraldDivision of Pulmonary Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada.
Sean van DiepenDepartment Critical Care Medicine and Division of Cardiology, Department of Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada.
Michael K SticklandDivision of Pulmonary Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada; G.F. MacDonald Centre for Lung Health, Covenant Health, Edmonton, AB, Canada. Electronic address: michael.stickland@ualberta.ca.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPatients with advanced COPD have pulmonary vascular dysfunction and destruction; thus, it is unclear whether they are responsive to selective pulmonary vasodilators. RESEARCH QUESTION: What is the effect of inhaled nitric oxide (iNO) on exercise capacity in patients without hypoxemia with mild-to-severe COPD without pulmonary hypertension, and are there structural and/or functional predictors of response? STUDY DESIGN AND

methodsSixty-one patients with mild-to-severe COPD (mean FEV

resultsThe mean effect of iNO on Vo

interpretationOur results show that despite a null mean effect of iNO on Vo CLINICAL

trial registrationClinicalTrials.gov; No.: NCT03679312; URL: www. CLINICALTRIALS: gov.

Indexed as

Exercise ToleranceNitric OxidePulmonary Disease, Chronic ObstructiveVasodilator AgentsAdministration, InhalationAgedCross-Over StudiesDouble-Blind MethodEchocardiographyExercise TestFemaleHumansMaleMiddle AgedOxygen ConsumptionRespiratory Function TestsNitric OxideVasodilator AgentsCOPDCT scanexerciseimaginglung physiology

Identifiers

PMID41895703
PMCPMC13269684

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.